Compare IDEXX Laboratories, Inc. (IDXX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs J M Smucker Co — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while J M Smucker Co trades at $119.83 (market cap $12.76B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.2× J M Smucker Co's market cap, and J M Smucker Co pays a 3.75% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and J M Smucker Co for 74 Days on average.
| IDXX | SJM | |
|---|---|---|
Market Cap | $40.43B | $12.76B |
Volume | 692,164 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $132.34 |
52-Week Low | $504.70 | $89.53 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | $41.32B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
SJM stock trades at $119.41, up 3.0% with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The company maintains strong cash flow from operations at $1.21B and recently raised FY27 EPS guidance to $10.50-$11.00. However, 2025 results showed a net loss of $1.23B despite $8.73B revenue, with elevated P/E ratio of 55.8 suggesting premium valuation.
Outlook remains cautiously optimistic with analyst consensus target of $138.23 (16% upside) and 52% buy ratings, though high debt levels and margin pressures present risks. The stock offers dividend income with upcoming $1.12 payment, while technical support at $118 provides near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
